- Home
- APLM vs ZAPP Comparison
APLM vs ZAPP Comparison
Compare APLM & ZAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- ZAPP
- Stock Information
- Founded
- APLM 2016
- ZAPP 2017
- Country
- APLM United States
- ZAPP Thailand
- Employees
- APLM N/A
- ZAPP N/A
- Industry
- APLM Blank Checks
- ZAPP Motor Vehicles
- Sector
- APLM Finance
- ZAPP Consumer Discretionary
- Exchange
- APLM Nasdaq
- ZAPP Nasdaq
- Market Cap
- APLM 12.3M
- ZAPP 5.1M
- IPO Year
- APLM N/A
- ZAPP N/A
- Fundamental
- Price
- APLM $7.55
- ZAPP $0.79
- Analyst Decision
- APLM Strong Buy
- ZAPP
- Analyst Count
- APLM 2
- ZAPP 0
- Target Price
- APLM $425.00
- ZAPP N/A
- AVG Volume (30 Days)
- APLM 4.3K
- ZAPP 154.0K
- Earning Date
- APLM 03-18-2025
- ZAPP 01-31-2025
- Dividend Yield
- APLM N/A
- ZAPP N/A
- EPS Growth
- APLM N/A
- ZAPP N/A
- EPS
- APLM N/A
- ZAPP N/A
- Revenue
- APLM $2,101,000.00
- ZAPP $17,440.00
- Revenue This Year
- APLM N/A
- ZAPP $67,159.17
- Revenue Next Year
- APLM N/A
- ZAPP $1,149.53
- P/E Ratio
- APLM N/A
- ZAPP N/A
- Revenue Growth
- APLM 70.54
- ZAPP N/A
- 52 Week Low
- APLM $6.20
- ZAPP $0.66
- 52 Week High
- APLM $76.10
- ZAPP $19.10
- Technical
- Relative Strength Index (RSI)
- APLM 52.15
- ZAPP 42.17
- Support Level
- APLM $6.30
- ZAPP $0.66
- Resistance Level
- APLM $6.70
- ZAPP $0.86
- Average True Range (ATR)
- APLM 0.42
- ZAPP 0.07
- MACD
- APLM 0.12
- ZAPP 0.02
- Stochastic Oscillator
- APLM 96.43
- ZAPP 51.60
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About ZAPP Zapp Electric Vehicles Group Limited
Zapp Electric Vehicles Group Ltd designs manufactures, and sells high-performance electric vehicles, including maintenance and repair of electric vehicles and related parts and accessories. Companies founders are automotive professionals from all over the world who share a commitment to sustainability, a long passion for electric vehicles, motorcycles, and believe in the choice of personal urban mobility. The company operates in Cayman Islands, Europe, Thailand. Maximum of revenue is from Thailand.